Condensed Consolidated Statements of Operations (unaudited) (USD $) In Thousands, except Share data	3 Months Ended		9 Months Ended
	Sep. 30, 2011	Sep. 30, 2010	Sep. 30, 2011	Sep. 30, 2010
Revenues:
Product sales	$ 1,945	$ 1,531	$ 5,030	$ 3,814
Research and development income	119	165	539	348
Licensing and royalty income	23	48	99	206
Other revenue	26		43
Total revenues	2,113	1,744	5,711	4,368
Cost and expenses:
Cost of sales	1,479	1,286	4,113	3,760
Selling, general and administrative expenses	609	760	2,300	2,482
Product development and research expenses	442	373	1,573	1,027
Total costs and expenses	2,530	2,419	7,986	7,269
Operating loss	(417)	(675)	(2,275)	(2,901)
Interest income (expense) and other	(70)	(4)	(193)	(1)
Net loss	(487)	(679)	(2,468)	(2,902)
Preferred stock dividends		(1,284)		(1,284)
Net Loss Attributable to Common Stockholders	$ (487)	$ (1,963)	$ (2,468)	$ (4,186)
Basic and diluted loss per share (in Dollars per share)	$ (0.01)	$ (0.08)	$ (0.06)	$ (0.21)
Weighted Average of Common Stock and Common Stock Equivalents Outstanding
Basic and diluted (in Shares)	39,498,096	24,876,399	39,432,061	20,071,518